Phase I/II study of peptide vaccination associated with GM-CT-01, a galactomannan oligomer that inhibits galestin-3, in patients with advanced metastatic melanoma - Peptide vaccinations plus GM-CT-01 in melanoma

Start Date23 Apr 2012

Sponsor / Collaborator

Cliniques Universitaires Saint-Luc

NCT01723813 / TerminatedPhase 1/2IIT

Phase I/II Study of Peptide Vaccination Associated With GM-CT-01, a Galactomannan Oligomer That Inhibits Galectin-3, in Patients With Advanced Metastatic Melanoma

The purpose of this study is to determine whether the intravenous and/or GM-CT-01 administration can correct Tumor Infiltrating Lymphocytes (TIL) anergy and induce a more efficient and long-lasting anti-tumoral immune response following peptide vaccination.

Start Date01 Apr 2012

Sponsor / Collaborator

Cliniques Universitaires Saint-Luc

NCT00388700 / WithdrawnPhase 2

Open-Label, Phase 2 Study of GM-CT-01 When Added to a Regimen of Leucovorin, 5-FU, and Avastin as First Line Treatment for Locally Advanced, Unresectable or Metastatic Colorectal Cancer in Subjects Unable to Tolerate Intensive Chemotherapy

The purpose of this clinical trial is to determine whether the combination of 5-fluorouracil (5-FU) plus a DAVANAT (carbohydrate polymer) along with Avastin and Leucovorin (LV) is beneficial in treating colorectal cancer in patients unable to tolerate intensive chemotherapy.

Start Date01 Oct 2006

Sponsor / Collaborator

Galectin Therapeutics, Inc.

100 Clinical Results associated with Galactomannan C

100 Translational Medicine associated with Galactomannan C

100 Patents (Medical) associated with Galactomannan C

Literatures (Medical) associated with Galactomannan C

01 Jun 2024·Medicine & Science in Sports & Exercise

Recovery during Successive 120-min Football Games: Results from the 120-min Placebo/Carbohydrate Randomized Controlled Trial

Article

Author: Liakou, Christina ; Ermidis, Georgios ; Chatzinikolaou, Athanasios ; Draganidis, Dimitrios ; Sovatzidis, Apostolos ; Fatouros, Ioannis G. ; Vigh-Larsen, Jeppe F. ; Papadopoulos, Constantinos ; Jamurtas, Athanasios Z. ; Georgakouli, Kalliopi ; Deli, Chariklia K. ; Papadimas, Giorgos ; Rosvoglou, Anastasia ; Papanikolaou, Konstantinos ; Tsimeas, Panagiotis ; Krustrup, Peter ; Poulios, Athanasios ; Douroudos, Ioannis I. ; Mohr, Magni ; Loules, Georgios ; Nakopoulou, Theofano

ABSTRACTPurposeThis study aimed to examine the recovery kinetics (i.e., time-dependent changes) of performance-related variables between two 120-min male football games performed 3 d apart with and without carbohydrate supplementation.MethodsTwenty male players (20 ± 1 yr; body fat, 14.9% ± 5.1%; maximal oxygen consumption, 59.4 ± 3.7 mL·kg−1·min−1) participated in two 120-min football games (G1, G2) according to a randomized, two-trial, repeated-measures, crossover, double-blind design. Participants received carbohydrate/placebo supplements during recovery between games. Field activity was monitored during the games. Performance testing and blood sampling were performed before and at 90 and 120 min of each game. Muscle biopsies were collected at baseline and at 90 and 120 min of G1 and pre-G2.ResultsCompared with G1, G2 was associated with reduced total distance (10,870 vs 10,685 m during 90 min and 3327 vs 3089 m during extra 30 min;P= 0.007–0.038), average (6.7 vs 6.2 km/h during extra 30-min game-play;P= 0.007) and maximal speed (32.2 vs 30.2 km/h during 90 min and 29.0 vs 27.9 km/h during extra 30 min;P< 0.05), accelerations/decelerations (P< 0.05), and mean heart rate (P< 0.05). Repeated sprint ability (P< 0.001), jumping (P< 0.05), and strength (P< 0.001) performance were compromised before and during G2. Muscle glycogen was not restored at G2 baseline (P= 0.005). Extended game-play reduced lymphocyte, erythrocyte counts, hematocrit, hemoglobin, reduced glutathione (P< 0.05) and increased delayed onset of muscle soreness, creatine kinase activity, blood glycerol, ammonia, and protein carbonyls (P< 0.05) before and during G2. Pax7+(P= 0.004) and MyoD+cells (P= 0.019) increased at baseline G2. Carbohydrate supplementation restored performance and glycogen, reduced glycerol and delayed onset of muscle soreness responses, and increased leukocyte counts and Pax7+and MyoD+cells.ConclusionsResults suggest that extended football games induce a prolonged recovery of performance, which may be facilitated by carbohydrate supplementation during a congested game fixture.

01 Nov 2022·Sports Medicine

The Ergogenic Effects of Acute Carbohydrate Feeding on Resistance Exercise Performance: A Systematic Review and Meta-analysis

Review

Author: Zinn, Caryn ; King, Andrew ; Helms, Eric ; Jukic, Ivan

AbstractBackgroundCarbohydrate (CHO) ingestion has an ergogenic effect on endurance training performance. Less is known about the effect of acute CHO ingestion on resistance training (RT) performance and equivocal results are reported in the literature.ObjectiveThe current systematic review and meta-analysis sought to determine if and to what degree CHO ingestion influences RT performance.MethodsPubMed, MEDLINE, SportDiscus, Scopus, and CINAHL databases were searched for peer-reviewed articles written in English that used a cross-over design to assess the acute effect of CHO ingestion on RT performance outcomes (e.g., muscle strength, power, and endurance) in healthy human participants compared to a placebo or water-only conditions. The Cochrane Collaboration’s risk of bias tool and GRADE approaches were used to assess risk of bias and certainty of evidence, respectively. Random effects meta-analyses were performed for total training session volume and post-exercise blood lactate and glucose. Sub-group meta-analysis and meta-regression were performed for categorical (session and fast durations) and continuous (total number of maximal effort sets, load used, and CHO dose) covariates, respectively.ResultsTwenty-one studies met the inclusion criteria (n = 226 participants). Pooled results revealed a significant benefit of CHO ingestion in comparison to a placebo or control for total session training volume (standardised mean difference [SMD] = 0.61). Sub-group analysis revealed a significant benefit of CHO ingestion during sessions longer than 45 min (SMD = 1.02) and after a fast duration of 8 h or longer (SMD = 0.39). Pooled results revealed elevated post-exercise blood lactate (SMD = 0.58) and blood glucose (SMD = 2.36) with CHO ingestion. Meta-regression indicated that the number of maximal effort sets, but not CHO dose or load used, moderates the effect of CHO ingestion on RT performance (beta co-efficient [b] = 0.11). Carbohydrate dose does not moderate post-exercise lactate accumulation nor do maximal effort sets completed, load used, and CHO dose moderate the effect of CHO ingestion on post-exercise blood glucose.ConclusionsCarbohydrate ingestion has an ergogenic effect on RT performance by enhancing volume performance, which is more likely to occur when sessions exceed 45 min and where the fast duration is ≥ 8 h. Further, the effect is moderated by the number of maximal effort sets completed, but not the load used or CHO dose. Post-exercise blood lactate is elevated following CHO ingestion but may come at the expense of an extended time-course of recovery due to the additional training volume performed. Post-exercise blood glucose is elevated when CHO is ingested during RT, but it is presently unclear if it has an impact on RT performance.Protocol RegistrationThe original protocol was prospectively registered on the Open Science Framework (Project identifier: https://doi.org/10.17605/OSF.IO/HJFBW).

01 Feb 2021·International Journal of Sports MedicineQ4 · MEDICINE

Caffeine Supplementation or Carbohydrate Mouth Rinse Improves Performance

Q4 · MEDICINE

Article

Author: Azevedo, Katia ; Pereira, Paulo Eduardo Assis ; Azevedo, Paulo ; Machado, Marco ; Azevedo, Warleyson

AbstractTraining volume is one of the critical variables required to promote resistance training benefits (e. g., hypertrophy, muscular strength). Thus, strategies to improve training volume are required. We tested the hypothesis that there is an increase in performance and reduction in the rate of perceived exertion in strength training with caffeine supplementation, carbohydrate mouth rinse, and a synergistic effect of caffeine supplementation plus carbohydrate mouth rinse. We recruited 29 physically active women: 24±4 years, 60.0±7.9 kg, 161.0±6.0 cm. This study was a double-blind, randomized, placebo-controlled, and crossover one. The subjects performed all sessions of strength training under different conditions: caffeine (6.5 mg·kg−1 body mass); carbohydrate (6 g of maltodextrin rinsed for 10 s); caffeine plus carbohydrate; or placebo. We applied the ANOVA for repeated measures through the null-hypothesis statistical test, and the Bayes factors analyses approach. The subjects showed significant improvement in the total repetitions (P<0.01; BF10 ~99%) for both lower and upper limb exercises in all conditions compared to placebo without difference among interventions. The rate of perceived exertion (P>0.05) did not differ among interventions. However, BF10 analyses showed a higher probability of lower RPE for CAF intervention. We conclude that either caffeine supplementation or carbohydrate mouth rinse can improve performance in resistance training. There is no additional effect of caffeine plus carbohydrate.

News (Medical) associated with Galactomannan C

29 Apr 2009

·www.biospace.com

Pro-Pharmaceuticals, Inc. Engages Perceptive Imagineering, LLC to Market DAVANAT(R) in Central & South America

NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (OTCBB: PRWP), a bio-pharmaceutical company developing proprietary therapeutic compounds to treat cancer and fibrosis, has entered into a consulting agreement with Perceptive Imagineering, LLC (“Perceptive”) to represent the Company in Central and South America. Starting in Colombia, Perceptive will conduct registration, marketing, sales and support for the licensing and distribution of DAVANAT® throughout the region to treat colorectal cancer in combination with approved chemotherapy drugs. Next steps are to finalize an export license and to select an established partner for distribution. Perceptive also will develop a website for Pro-Pharmaceuticals specifically designed for the Latin American market.

Collaborate

01 May 2008

·www.biospace.com

Pro-Pharmaceuticals, Inc. Updates NDA Filing for DAVANAT(R)

NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex: PRW), a Company developing targeted therapeutic compounds to treat cancer and fibrosis, today announced the receipt of the manufacturing and certification data for DAVANAT® from SAFC®, the custom manufacturing services division of Sigma-AldrichTM (Nasdaq: SIAL). The manufacturing and validation data is under final independent audit and is needed for registration of a pharmaceutical ingredient. The Company plans to submit the Drug Master File (DMF) shortly to the U.S. Food and Drug Administration (FDA). The DMF submission is an important step in the Company’s plan to New Drug Application (NDA) for DAVANAT® later this year.

23 Jan 2007

·www.biospace.com

Pro-Pharmaceuticals, Inc. Announces Dosing Of Patients With DAVANAT(R) In Phase II, First Line, Advanced Biliary Cancer Clinical Trial

NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex:PRW), a developer of novel carbohydrate compounds, today announced the dosing of patients in its Phase II, first line, biliary cancer trial. The Phase II trial is an open-label, multi-center trial of DAVANAT® with 5-Fluorouracil (5-FU) to treat patients with advanced bile duct and gall bladder cancer.

100 Deals associated with Galactomannan C

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15311

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bile Duct Neoplasms	NDA/BLA	US	Galectin Therapeutics, Inc.	01 Sep 2006
Gallbladder Neoplasms	NDA/BLA	US	Galectin Therapeutics, Inc.	01 Sep 2006
Metastatic Colorectal Carcinoma	NDA/BLA	US	Galectin Therapeutics, Inc.	01 May 2005
Metastatic Colorectal Carcinoma	NDA/BLA	IL	Galectin Therapeutics, Inc.	01 May 2005
Advanced Malignant Solid Neoplasm	NDA/BLA	US	Galectin Therapeutics, Inc.	01 Feb 2003
Breast Cancer	NDA/BLA	US	Galectin Therapeutics, Inc.	01 Feb 2003
Head and Neck Neoplasms	NDA/BLA	US	Galectin Therapeutics, Inc.	01 Feb 2003
Lung Cancer	NDA/BLA	US	Galectin Therapeutics, Inc.	01 Feb 2003
Colorectal Cancer	NDA/BLA	CO	Galectin Therapeutics, Inc.	-
Melanoma	NDA/BLA	BE	Galectin Therapeutics, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis